[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pituitary-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pituitary-adenoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,49,76,98,124,149,178,197,217,241,269,301,324,352,373,403,430,452,477,497],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100630882","early-phase-1-pilot-study-evaluating-panitumumab-irdye800-as-an-optical-imaging-agent-to-detect-intracranial-lesions-during-neurosurgical-procedures-100630882",false,"NCT07493447","Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures","Inclusion Criteria:\n\n* Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and\u002For radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection.\n* Subject age ≥ 18 years.\n* Adequate hematologic and end-organ function appropriate for surgery and panitumumab infusion as determined by routine preoperative evaluation or designee prior to infusion. If liver function, renal function, and hematologic laboratory test results are acceptable for elective surgery and panitumumab infusion, the patient is considered eligible for the study. Laboratory results will need to be obtained within 30 days prior to initiation of study treatment include:\n\n  1. Chemistry Panel - Potassium, BUN (or urea), and Creatinine\n  2. CBC with differential - WBC, including ANC, hemoglobin, hematocrit, and platelet count\n  3. Magnesium and Phosphorus\n* Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration.\n* Ability to understand and willingness to sign a written informed document or written informed consent via a surrogate consent rider from the patients' healthcare decision maker.\n\nExclusion Criteria:\n\n* Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment.\n* History of infusion reactions to any monoclonal antibody therapies.\n* Women who are currently pregnant or breastfeeding.\n* Participants presenting with a baseline QTcF interval \\> than 480 milliseconds.\n* Magnesium or phosphorus lower than normal institutional values, and subject is symptomatic.\n* Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n* Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n* Patients with severe renal disease or anuria","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.",[25,26,27,28,29],"Meningioma","Glioblastoma","Acoustic Neuroma","Brain Cancer","Pituitary Adenoma",[31,32,33,26,25,29,27,34,35],"Cancer","Malignant","Benign","Brain Masses","Intracranial Lesion","RECRUITING","2026-06-26",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":19},"2026-07",{"date":44,"type":19},"2031-06",{"name":46,"class":47},"Eben Rosenthal","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100617244","clinical-trial-of-an-anti-fog-drainage-device-for-endoscopic-endonasal-sellar-region-tumor-surgery-100617244","NCT07316101","Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery","Inclusion Criteria:\n\n* Age 18-75 years\n* Pre-operative MRI\u002FCT diagnosis of pituitary adenoma or craniopharyngioma ≤ \\*3 cm without extensive skull-base invasion\n* Scheduled for elective endoscopic endonasal transsphenoidal resection\n* ASA physical status I-III\n* Able and willing to give written informed consent and comply with follow-up\n\nExclusion Criteria:\n\n* Severe nasal anatomical deformity, polyps, or prior nasal surgery preventing device placement\n* Active nasal or systemic infection (WBC \\> 10 × 10⁹\u002FL, CRP ≥ 10 mg\u002FL)\n* Known intracranial infection or ongoing CSF leak\n* Coagulopathy (PT \\> 14 s or APTT \\> 45 s) or anticoagulation that cannot be stopped ≥ 7 days\n* Allergy to silicone or medical-grade plastics\n* Planned combined transcranial or transorbital approach\n* Pregnancy or breastfeeding\n* Psychiatric or cognitive disorder precluding informed consent or follow-up","75 Years",{"count":5,"type":19},[58],"NA","The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device.\n\nThe main questions it aims to answer are:\n\n* Does the device reduce the total time the surgeon has to stop because the lens fogs up?\n* What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used?\n\nResearchers will compare the anti-fog device to the usual \"water-squirt\" method to see if the device works better.\n\nParticipants will:\n\n* Have either the device or the usual water method applied during their planned pituitary surgery\n* Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7\n* Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery",[29,61],"Craniopharyngioma",[63,64,65,66,67,68],"endoscopic endonasal surgery","pituitary adenoma","anti-fog device","suction irrigation","intracranial infection","randomized controlled trial",{"date":39,"type":40},{"date":71,"type":40},"2026-03-01",{"date":73,"type":19},"2026-12-31",{"name":75,"class":47},"West China Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":20,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":48},"100628330","early-phase-1-fet-petct-imaging-to-localize-pituitary-adenomas-in-cushing-disease-100628330","NCT07460232","FET PET\u002FCT Imaging To Localize Pituitary Adenomas In Cushing Disease","18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease","Inclusion Criteria:\n\nPatients must meet ALL criteria listed below for entry:\n\n* Biochemically diagnosed ACTH-dependent Cushing disease.\n* No previous pituitary surgery.\n* Planned to undergo pituitary surgery for localization\u002Fresection of adenoma.\n* No contraindications for PET\u002FCT.\n* Recent (within 3 months) pituitary MR, or pending pituitary MR to be performed as close as possible to FET PET\u002FCT.\n* Age ≥ 18 years.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential\n* Declining to use effective contraceptive methods during the study (for individuals of child-bearing potential)\n* Need for emergent surgery that would be delayed by participation\n* Bacterial, viral, or fungal infections requiring systemic therapy\n* Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or autoimmune diseases or other conditions) that in the opinion of the investigator could compromise patient safety and\u002For protocol objectives\n* Known diagnosis of autoimmune disorders\n* Patients receiving any other investigational agent within the past 28 days\n* Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the FET injection.\n* Known hypersensitivity to any excipients used in FET",{"count":84,"type":19},50,[22],"The purpose of this research is to evaluate the performance \\[sensitivity, specificity, accuracy\\] of FET PET\u002FCT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.",[88,29],"Cushing Disease","2026-06-17",{"date":91,"type":40},"2026-06-22",{"date":93,"type":40},"2026-04-27",{"date":95,"type":19},"2028-07",{"name":97,"class":47},"Mayo Clinic",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100639026","standardized-patient-education-in-pituitary-surgery-100639026","NCT07618949","Standardized Patient Education in Pituitary Surgery","The Impact of Standardized Patient Education on Patient Outcomes in Transsphenoidal Pituitary Surgery","Inclusion Criteria:\n\n* Admitted for elective surgery due to a pituitary tumor.\n* Has not previously undergone surgery for the same medical condition.\n* Has voluntarily agreed to participate in the study.\n* Has no missing medical data.\n* Can speak Turkish or understand what is being explained.\n* Patients aged 18 and older.\n\nExclusion Criteria:\n\n* Emergency surgery will be performed.\n* Revision surgery will be performed.\n* Those who voluntarily decline to participate in the study.\n* Those with incomplete medical data.\n* Those who cannot speak or understand Turkish.\n* Patients under the age of 18.",{"count":106,"type":19},102,[58],"Protocols are being developed and implemented to ensure the best possible recovery process for patients undergoing transsphenoidal surgery, and their impact on patient outcomes is being evaluated. In studies where perioperative protocols-including patient education (verbal and written instruction on dehydration, hyponatremia, adrenal insufficiency, CSF leakage, meningitis, and the signs and symptoms of visual or other neurological disorders)-are implemented, it has been reported that patients' length of hospital stay is reduced, the rate of patients experiencing hyponatremia has decreased, and readmissions have declined (Sanchez-Garavito et al., 2024; Sarris et al., 2021). However, since these studies included protocols covering the entire surgical process-not just patient education-it is difficult to determine whether changes in patient outcomes stem from patient education or from alterations in other parameters within the protocol.\n\nTherefore, in the clinic where this study will be conducted, the effect of patient education on postoperative patient outcomes will be examined by developing an educational material that standardizes patient education, without making any changes to the surgical or pharmacological processes.",[29],[111,112,113],"Pituitary tumor","transsphenoidal surgery","Patient education","NOT_YET_RECRUITING","2026-05-24",{"date":117,"type":40},"2026-06-01",{"date":119,"type":19},"2026-06",{"date":121,"type":19},"2027-09",{"name":123,"class":47},"Uludag University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":20,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100636644","early-phase-1-ai-in-endoscopic-transsphenoidal-surgery-100636644","NCT07568366","AI in Endoscopic Transsphenoidal Surgery","The Application of Artificial Intelligence to Patients Undergoing Endoscopic Transsphenoidal Surgery: a Single-site Prospective Feasibility and Exploratory Study (IDEAL Stage 1 and 2a)","The inclusion criteria will be:\n\n1. Adult patients (above the age of 18 years old)\n2. Undergoing endoscopic transsphenoidal surgery\n3. Able to provide consent\n\nThe exclusion criteria will be:\n\n1. Patients less than 18 years of age\n2. Undergoing transcranial surgery or microscopic transsphenoidal surgery\n3. Unable to provide consent e.g., cannot understand, mental illness, or later withdrawing consent",{"count":18,"type":19},[22],"This study focuses on bringing artificial intelligence into the operating room to assist with pituitary tumour surgeries performed through the nose. These procedures are technically demanding, and training new surgeons is often inconsistent. To address this, researchers at the National Hospital for Neurology and Neurosurgery are testing AI systems that \"watch\" surgical videos in real-time to identify anatomy, instruments, and the specific phase of the operation.\n\nThe core goal of the prospective trial is to improve education and team coordination without interfering with the surgery itself. The AI displays its analysis on tablets positioned for the surgical residents and nurses, rather than the lead surgeon. This setup allows the team to follow the procedure's progress, key anatomy and anticipate next steps without the surgeon needing to stop and explain. Because hospital internet can be unreliable, the study is prioritizing specialized hardware from NVIDIA that processes data locally. This \"edge computing\" approach ensures the AI is fast and doesn't require a live cloud connection to function.\n\nThis trial will assess the device feasibility (IDEAL Stage 1 study, \\~6 cases), followed by early safety and system technical refinement (IDEAL 2a study, \\~20-30 cases).",[29],[136,137,138,139,64,140],"Artificial intelligence","computer vision","surgical technology","technology translation","endoscopic surgery","2026-04-30",{"date":143,"type":40},"2026-05-05",{"date":117,"type":19},{"date":146,"type":19},"2029-01-31",{"name":148,"class":47},"University College, London",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":15,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":20,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":48},"100406221","ddavp-for-pituitary-adenoma-100406221","NCT04569591","DDAVP for Pituitary Adenoma","Desmopressin (DDAVP) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Subjects aged 8 or older with biochemical evidence of Cushing s disease and a clinical MRI pituitary neuroradiology result of negative or possible adenoma (e.g. \"no tumor\" or \"possible tumor\")\n2. MRI of the pituitary gland with and without contrast obtained within 9 months of screening\n3. For newly diagnosed Cushing s disease cases, IPSS is required.\n4. Ability to undergo PET-imaging without general anesthesia\n5. Ability to provide informed consent for study participation (parents or guardians in the case of minors)\n6. Clinical diagnosis of Cushing s disease based on documented medical records\n7. Surgical candidate for and subject agrees to resection of ACTH producing pituitary adenoma within 24 weeks of PET-imaging\n8. Normal liver function as evidenced by liver enzyme tests completed within 14 days before injection of radiopharmaceutical: SGOT, SGPT \\\u003C= 5 x upper limit of normal; bilirubin \\\u003C= 2 x upper limit of normal\n9. Tolerance of a previous infusion of DDAVP, including as part of workup and diagnosis of Cushing's disease\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current pregnancy or lactation\n2. Glomerular filtration rate \\\u003C 50 mL\u002Fmin\u002F1.73 m\\^2, hepatorenal syndrome, history of urinary retention or post-liver or kidney transplantation.\n3. Hyponatremia (serum sodium below 135 mmol\u002FL)\n4. Current diagnosis of angina, significant coronary artery disease, congestive heart failure, or SIADH due to risk of fluid overload and\u002For hyponatremia.\n5. Uncontrolled hypertension (blood pressure \\>150\u002F95 mmHg) due to risk of further increase if fluid overload occurs.\n6. Uncontrolled, severe hypotension (sustained blood pressure \\\u003C90\u002F60), or symptomatic hypotension.\n7. Current use of any of the following medications:\n\n   * Vasopressors: phenylephrine, dopamine and vasopressin\n   * Drugs that can worsen hyponatremia: non-steroidal anti-inflammatory drugs (NSAIDs) within 4 days of testing, loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide), chlorpromazine, chlorpropamide, cisplatin, opiate agonists within 48 hours of testing, and\u002For vincristine.\n   * Drugs that interfere with DDAVP duration of action or potency: carbamazepine, lamotrigine, and\u002For tolvaptan\n8. Habitual or psychogenic polydipsia, due to increased risk of hyponatremia\n9. History of Type IIB von Willebrand s disease due to risk for thrombosis.\n10. Elevated blood glucose level above 200 mg\u002FdL on the day of the scan prior to FDG administration.\n11. Known intolerance to DDAVP\n\nINCLUSION OF VULNERABLE PARTICIPANTS:\n\n* Children: Children age 8 and older are included in this protocol. More than half of the subjects with CD requiring transsphenoidal surgery at the NIH are children. The knowledge gained by the use of DDAVP PET imaging in children with MR-invisible tumors will provide generalizable knowledge in the treatment of CD in this population. Children under the age of 8 usually require anesthesia for a PET scan, which involves greater risk. Therefore, children under the age of 8 will be excluded from participation.\n* Pregnant or lactating women: Pregnant and lactating women will be excluded from participation. The PET radiopharmaceutical used in this study can be harmful to a developing fetus. Therefore women who are able to become pregnant will have a pregnancy test performed within 24 hours before PET imaging. Individuals will not be able to participate in PET scanning if the pregnancy test results positive.","8 Years","99 Years",{"count":159,"type":19},22,[58],"This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituitary adenomas in patients with Cushing s disease. Patients who have MRI-negative pituitary microadenomas will undergo FDG PET-imaging with DDAVP stimulation. Intravenous FDG will be given approximately four hours following DDAVP administration. Within 12 weeks after completion of the FDG high-resolution PET scan, patients will undergo surgical resection of the pituitary adenoma. Surgical and histological confirmation of adenoma location will be noted. All images will be read independently by neuroradiologists blinded to clinical and histopathological outcomes. The diagnostic and localization accuracy of PET-imaging will be assessed by comparing the PET findings with histopathology.",[163,29],"Cushing's Disease",[165,166,167],"Corticotropinoma","Pituitary Microadenoma","Acthrel","2026-04-08",{"date":170,"type":40},"2026-04-09",{"date":172,"type":40},"2026-03-09",{"date":174,"type":19},"2028-02-26",{"name":176,"class":177},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":184,"targetDuration":4,"studyType":20,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":48},"100628072","phase-1-use-of-18f-fluoroethyl-l-tyrosine-petmri-for-identifying-small-functional-pituitary-adenomas-100628072","NCT07456878","Use of [18F] Fluoroethyl-L-tyrosine PET\u002FMRI for Identifying Small Functional Pituitary Adenomas","Inclusion Criteria:\n\n* Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.\n* Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.\n* Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.\n* Able to provide informed consent and be capable of completing the imaging protocols.\n* Female subjects of childbearing potential (women of childbearing potential \\[WOCBP\\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.\n\nExclusion Criteria:\n\n* Patients with contraindications to MRI or PET scans.\n* Patients with known allergies to contrast agents or other imaging-related materials.\n* Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).\n* Patients with successful MRI localization of the adenoma.",{"count":185,"type":19},5,[187],"PHASE1","The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET\u002FMRI in detecting MRI-occult primary or residual\u002Frecurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.",[29],"2026-03-03",{"date":172,"type":40},{"date":193,"type":40},"2026-01-08",{"date":195,"type":19},"2026-12",{"name":97,"class":47},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":205,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":48},"100618722","evaluation-of-intraoperative-contrast-enhanced-ultrasound-for-the-identification-of-pituitary-adenoma-in-cushings-disease-compared-to-other-pituitary-tumors-100618722","NCT07335315","Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors","For Contrast Based Protocol:\n\nInclusion Criteria:\n\n* Diagnosis of Cushing disease or required resection for non-corticotroph adenomas\n* Agree to transsphenoidal resection.\n\nExclusion Criteria:\n\n* Patients who are unable to consent (or if their legal guardian\u002Frepresentative decline to consent)\n* Patients who have known or suspected hypersensitivity to microbubble contrast agents or its components such as polyethylene glycol (PEG).\n* Women of child-bearing potential with a positive pregnancy test prior to procedure.\n* Patients who have right to left, bi-directional, or transient right to left cardiac shunts.\n* Patients who have hypersensitivity to perflutren.\n\nFor Non-Contrast Based Protocol:\n\nInclusion Criteria:\n\n* Patients undergoing any pituitary surgery with the study designated neurosurgeons.\n* Patients whose procedures require the use of an intra-operative BK ultrasound without contrast.\n\nExclusion Criteria:\n\n• Patients who are unable to consent (or if their legal guardian\u002Frepresentative decline to consent)",{"count":204,"type":19},110,"6 Months","OBSERVATIONAL","This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for lesion-specific surgical resection to impact clinical outcome. Should this imaging approach help isolate specific lesions and prevent surgical resection of normal pituitary tissue in this first-in-humans study, then the results will provide clinical data for a much larger multi-center clinical trial.",[29,88],"2026-01-05",{"date":211,"type":40},"2026-01-13",{"date":213,"type":40},"2024-06-19",{"date":215,"type":19},"2027-01",{"name":97,"class":47},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":20,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":48},"100560974","molecular-pituitary-imaging-using-18f-fet-pet-100560974","NCT06584123","Molecular Pituitary Imaging Using 18F-FET PET","Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)","FET-pit-PET","Inclusion criteria\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, age 18 or above\n* Presence of pituitary adenoma suspected on the basis of clinical\u002Fbiochemical and\u002For radiological findings\n* Previous 11C-Met-PET\u002FCT\n\nExclusion criteria\n\n* Inability to give informed consent\n* Pregnancy or suspected pregnancy\n* Inability to lie supine for 30-60 minutes\n* Patient body habitus above scanner dimensions\n* Known allergy to intravenous radiographic contrast agents","100 Years",{"count":5,"type":19},[58],"The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.",[29],[231,232,233],"Molecular pituitary imaging","Functional pituitary imaging","18F-FET PET",{"date":235,"type":40},"2026-01-06",{"date":237,"type":40},"2024-09-03",{"date":73,"type":19},{"name":240,"class":47},"University of Cambridge",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":225,"enrollmentInfo":249,"targetDuration":4,"studyType":20,"phases":251,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":48},"100368775","phase-4-68-ga-dotatate-petmri-in-the-diagnosis-and-management-of-somatostatin-receptor-positive-cns-tumors-100368775","NCT04081701","68-Ga DOTATATE PET\u002FMRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)\u002FMRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.","DOMINO-START","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Diagnosis of meningioma based on pathology reports and suspected recurrence or residual disease based on standard-of-care MRI\n* Additionally, patients with other somatostatin receptor 2 positive brain tumors, including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain will be considered for the purposes of obtaining feasibility data\n* As the investigator's institution, PET\u002FMRI scanner utilizes a 3 Tesla (T) magnet, patients who may be ineligible to undergo 3T MRI but may undergo 1.5 Tesla (T) MRI, will undergo a 1.5T MRI as per clinical standard-of-care and a Ga68-DOTATATE PET\u002FCT with the PET portion to be fused with the 1.5T MRI utilizing fusion software.\n\nExclusion Criteria:\n\n* Contraindications to gadolinium-based contrast agent\n* History of allergic reaction to Gallium-68-DOTATATE\n* Pregnancy",{"count":250,"type":19},200,[252],"PHASE4","The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain, such as small cell carcinoma of the lung. The study indication is to determine the diagnostic utility of 68Ga-DOTATATE PET\u002FMRI in the diagnosis and management of patients with SSTR-positive CNS tumors, specifically whether 68Ga-DOTATATE PET\u002FMRI demonstrates utility distinguishing between tumor recurrence and post-treatment change. To date, the utility of Ga-68-DOTATATE PET\u002FMRI in meningioma has not been explored. Investigators have over the past 3 months been able to accrue the largest case series of presently 12 patients in whom Ga-68-DOTATATE PET\u002FMRI demonstrated utility in the assessment of meningioma, including assessment for postsurgical\u002Fpostradiation recurrence, detection of additional lesions not visualized on MRI alone, and evaluation of osseous invasion. Based on this initial experience, investigators intend to study the impact of Ga-68-DOTATATE PET\u002FMRI in the assessment of the extent of residual tumor in patients status post meningioma resection, specifically in patients in whom tumor location limits resectability, patients with World Health Organization (WHO) grade II\u002FIII disease, and patients with history of stereotactic radiosurgery (SRS) who develop postradiation change.",[255,25,256,257,258,259,29],"CNS Tumors","Esthesioneuroblastoma","Hemangioblastoma","Medulloblastoma","Paraganglioma","2025-11-17",{"date":262,"type":40},"2025-11-21",{"date":264,"type":40},"2019-09-04",{"date":266,"type":19},"2038-12-31",{"name":268,"class":47},"Weill Medical College of Cornell University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":20,"phases":280,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100579989","proton-versus-photon-radiotherapy-in-adults-with-primary-brain-tumors-100579989","NCT06831461","Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors","Proton Versus Photon Radiotherapy In Adults With Primary Brain Tumors Evaluating Functional Survival: A Phase 3 Randomized Controlled Trial (PRIDE)","PRIDE","Inclusion Criteria:\n\n* Primary brain tumors\n* Age at irradiation: 18 to 70 years\n* Karnofsky Performance Status ≥ 60\n* Diagnosis (histopathological\u002F radiological) of primary brain tumor with an expected survival of \\>5 years (e.g., grade 2-3 diffuse glioma, low-grade glial\u002F glioneuronal tumors, ependymoma, meningioma, pituitary tumors, schwannoma, craniopharyngioma, etc.)\n* Planned for focal cranial radiotherapy\n* Informed consent taken\n\nExclusion Criteria:\n\n* Re-irradiation\n* Palliative radiotherapy\n* Multifocal or multicentric disease\n* Planned for whole brain irradiation or craniospinal irradiation\n* Planned for hypo-fractionated or stereotactic radiotherapy","70 Years",{"count":279,"type":19},156,[58],"This study will be done in adults with brain tumors having good prognosis requiring treatment with radiotherapy. The current practice for brain radiotherapy involves treatment using X rays (photon radiotherapy). Proton beam therapy is a more advanced form of delivering radiation, which allows the reduction of the dose of radiation to the parts of the brain surrounding the tumor. After treatment with photon radiotherapy, certain late effects of radiation, like memory decline, hormonal deficits, hearing loss, and worsening of neurological function, can occur in some patients. From the evaluation of dose profiling, proton beam therapy has the potential to reduce the possibility of side effects by reducing the dose to critical organs. However, there is no clinical data to demonstrate whether the theoretical dose reduction translates to a clinically meaningful benefit. In the proposed study, 156 patients will be randomly allocated to either proton or photon radiotherapy in 1: 1 ratio. The primary objective of the study is to explore whether proton therapy improves functional survival, which is life expectancy without recurrence, death, or complications from radiotherapy.",[283,284,25,29,285],"Primary Brain Tumors","Diffuse Glioma","Low Grade CNS Tumors",[287,288,289,290,291],"Proton Beam Therapy","Photon Radiotherapy","Brain Tumors","Neurocognition","Survival","2025-09-15",{"date":294,"type":40},"2025-09-16",{"date":296,"type":40},"2025-07-01",{"date":298,"type":19},"2032-12-31",{"name":300,"class":47},"Tata Memorial Centre",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":48},"100590930","a-twenty-years-experience-in-pituitary-disease-100590930","NCT06973824","A Twenty-years' Experience in Pituitary Disease.","A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors","TYEPDD","Inclusion Criteria:\n\n* Patients underwent surgery for pituitary tumors;\n* pathology diagnosis of pituitary tumors;\n* patients older then 18 years at diagnosis of pituitary tumors;\n* 2 years follow-up;\n\nExclusion Criteria:\n\n* age lower then 18 years\n* follow-up shorter than 2 years",{"count":310,"type":19},1600,"Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.",[29,313,314],"Pituitary Cancer","Pituitary Disease","2025-05-07",{"date":317,"type":40},"2025-05-15",{"date":319,"type":40},"2025-03-10",{"date":321,"type":19},"2028-04-30",{"name":323,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":331,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100583292","the-impact-of-endoscopic-endonasal-skull-base-surgery-on-olfaction-100583292","NCT06874426","The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction","Endo-Olfact","Inclusion Criteria:\n\n* Adult patients scheduled for endoscopic endonasal skull base surgery\n\nExclusion Criteria:\n\n* Pre-existing anosmia\n* Patients has a history of previous endoscopic endonasal skull base surgery",{"count":332,"type":19},154,"In this study, the research team will investigate the incidence and etiology of olfactory dysfunction following endoscopic endonasal skull base surgery, by combining clinical assessments with histomolecular analysis.",[25,314,29,61,335,336],"Endoscopic Pituitary Surgery","Olfactory Dysfunction",[338,339,340,341],"olfactory dysfunction","trigeminal dysfunction","endoscopic endonasal skull base surgery","pituitary surgery","2025-04-17",{"date":344,"type":40},"2025-04-23",{"date":346,"type":40},"2025-03-18",{"date":348,"type":19},"2029-09",{"name":350,"class":47},"Universitaire Ziekenhuizen KU Leuven",3,{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":359,"targetDuration":4,"studyType":20,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":48},"100568330","phase-4-hydrocortisone-in-hormone-replacement-therapy-for-large-pituitary-neuroendocrine-tumors-100568330","NCT06679816","Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors","Study on the Efficacy of Hydrocortisone in Perioperative Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors:a Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled Study","Inclusion Criteria:\n\n* (1) Age range: 18-70 years old;\n* (2) Accept PitNETs patients who can be treated with endoscopic transsphenoidal surgery;\n* (3) The maximum diameter of the tumor is ≥ 2 centimeters;\n* (4) Preoperative hypothalamic pituitary adrenal axis integrity;\n* (5) The subject or their legal representative signs the informed consent form\n\nExclusion Criteria:\n\n* (1) Patients with a history of Cushing's disease or adrenal insufficiency;\n* (2) Emergency and combined hormone therapy patients;\n* (3) Pituitary stroke patients;\n* (4) Patients lacking head magnetic resonance imaging;",{"count":360,"type":19},882,[252],"The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are:\n\n• Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency.\n\nParticipants will:\n\n* Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks\n* Visit the clinic three months after surgery for checkups and tests\n* Keep a diary of their symptoms",[29,364],"Pituitary Neuroendocrine Tumor","2025-01-13",{"date":367,"type":40},"2025-01-14",{"date":369,"type":40},"2024-12-04",{"date":39,"type":19},{"name":372,"class":47},"Beijing Tiantan Hospital",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":381,"targetDuration":383,"studyType":206,"phases":4,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":48},"100458790","seoul-cohort-of-brain-tumor-monitoring-study-solomon-100458790","NCT05254197","SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)","The Risk of Growth in Patients With Non-malignant Brain Tumor: SeOuL cOhort of Brain Tumor MONitoring (SOLOMON) Study","SOLOMON","Inclusion Criteria for retrospective cohort\n\n* Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998\n* Asymptomatic at first visit to the hospital\n* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit\n* Patients who have had two or more MRs at least 3 months apart\n* No previous radiotherapy or radiosurgery for the brain lesion\n* 18 years old or more\n\nInclusion Criteria for prospective cohort\n\n* Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less\n* Asymptomatic at first visit to the hospital\n* Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams\n* No previous radiotherapy or radiosurgery for the brain lesion\n* 18 years old or more\n* Patients who agree to participate by written consent\n\nExclusion Criteria\n\n* Patients who lost follow-up before the second MR exam\n* Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam\n* Patients suspected to have other than a neoplasm at follow-up MR exams",{"count":382,"type":19},3000,"15 Years","The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.",[386,25,387,29,388],"Brain Tumor, Primary","Schwannoma","Gliomas Benign",[390,391,25,387,392,393],"Non-malignant brain tumor","Benign brain tumor","Pituitary adenoma","Benign glioma","2024-11-30",{"date":396,"type":40},"2024-12-03",{"date":398,"type":40},"2001-01-01",{"date":400,"type":19},"2035-12-31",{"name":402,"class":47},"Seoul National University Hospital",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":413,"conditions":414,"keywords":418,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":428,"locationsCount":4},"100570022","osilodrostat-therapy-and-11c-methionine-pet-to-improve-corticotroph-adenoma-detection-100570022","NCT06701838","Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection","Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease","OPTIMAL","Inclusion Criteria:\n\nAll participants must meet all of the following inclusion criteria:\n\n* age 18 years and older newly diagnosed with Cushing's disease and no\u002F an equivocal surgical target on MRI pituitary or\n* age 18 years and older and previously undergone pituitary surgery for Cushing's disease and clinical and biochemical evidence of persistent\u002F recurrent hypercortisolaemia and no\u002F an equivocal surgical target on MRI pituitary.\n\nExclusion Criteria:\n\nPotential participants will be ineligible to enter the study if they meet any of the following exclusion criteria:\n\n* Absolute contraindication to osilodrostat therapy and\u002For 11C methionine PET.\n* Pregnancy or unwillingness to use secure contraception for the study duration (female participants only).\n* Unable to comply with study visit schedule.",{"count":412,"type":19},15,"Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress. But too much cortisol can lead to problems like weight gain, high blood pressure, diabetes, and changes in appearance, such as a round face or a hump on the back. People with Cushing's disease often gain weight around their belly and may get stretch marks. They might also feel emotional changes, tiredness, or weakness. This disease is usually caused by a small, non-cancerous growth in the pituitary gland called a 'pituitary adenoma.' The pituitary gland is a small organ at the base of the brain and controls many important functions.\n\nWhen someone is diagnosed with Cushing's disease, doctors typically use an MRI scan to look for the adenoma in the pituitary gland. If found, the adenoma can often be removed through surgery, which often cures the disease. This is the standard treatment for patients with Cushing's disease. However, MRIs only find the adenoma in about 60% of the time. If surgery isn't possible because the adenoma can't be located, doctors may use medication to lower cortisol levels.\n\nIn addition to the MRI, doctors might use a special PET\u002FCT scan to find the adenoma. This PET\u002FCT scan is not available everywhere, so the investigators refer our patients to Cambridge Hospital for this scan, which uses a special dye called 11C-methionine.\n\nThe investigators then review the scan with the teams from Imperial and Cambridge. If the PET\u002FCT scan shows where the adenoma is, the patient will be offered surgery. However, finding the adenoma can be challenging because they are often small and hard to distinguish from normal tissue.\n\nIf the adenoma isn't visible, the investigators will use medical treatment to lower cortisol. After a period of medical treatment, another MRI scan and PET\u002FCT scan will be done to see if the adenoma has become clearer. This second PET\u002FCT scan would not normally be part of routine clinical care. The investigators will then compare the results of the two scans to see if the special dye is showing a stronger signal, which can help us find the adenoma more accurately and improve the chance of curing Cushing's disease with surgery.",[415,416,29,417],"Cushing's Disease","Hypercortisolism","Pituitary ACTH Secreting Adenoma",[419,420,421,422],"Cushing's disease","Osilodrostat","11C-methionine PET","Corticotroph adenoma","2024-11-28",{"date":396,"type":40},{"date":396,"type":19},{"date":427,"type":19},"2026-07-05",{"name":429,"class":47},"Imperial College London",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":4},"100541207","neuroendocrine-mechanisms-in-adiposity-an-integrated-approach-to-the-characterization-of-potential-pharmacological-novel-targets-based-on-experimental-and-clinical-models-100541207","NCT06326853","Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models","Inclusion Criteria:\n\nObese patients affected and not by hypothalamic-pituitary diseases\n\nExclusion Criteria:\n\n1. Minor subjects;\n2. Pregnant and\u002For breastfeeding women;\n3. Patients suffering from states of primary and\u002For acquired immunodeficiencies, and\u002For serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening\u002Freacerbated\u002Fcompensated chronic pathologies);\n4. Patients unable to understand and sign the Informed Consent.",{"count":250,"type":19},"The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle\u002Fbone tissue",[439,440,29,441,442,443],"Endocrine Disorders","Adiposity","Cushing Syndrome","Acromegaly","Hypopituitarism","2024-06-10",{"date":446,"type":40},"2024-06-11",{"date":448,"type":19},"2024-07",{"date":195,"type":19},{"name":451,"class":47},"IRCCS San Raffaele",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":20,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":351},"100495163","neurocognition-after-radiotherapy-in-cns--and-skull-base-tumors-100495163","NCT05727605","Neurocognition After Radiotherapy in CNS- and Skull-base Tumors","Neurocognition After Radiotherapy in Adult Brain and Base of Skull Tumors","NARCiS","Inclusion Criteria:\n\n* Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation)\n\nExclusion Criteria:\n\n* Patients with tumours with poor prognostic characteristics:\n\n  * Incompletely resected IDH-wild-type glioma\n  * Completely resected IDH-wild-type and MGMT-promotor unmethylated glioma\n  * grade III meningioma\n  * H3K27M+ midline glioma\n* Patients with tumours requiring craniospinal irradiation (CSI)\u002Fwhole ventricular irradiation (WVI)\n* Hypofractionated\u002Fstereotactic radiation (fraction sizes \\> 2 Gy per fraction)\n* Inability to perform the cognitive tests or self-report inventories because of motor\u002Fsensory deficits or insufficient Dutch language proficiency\n* Mental retardation documented before diagnosis\n* Pre-diagnosis\u002Fpre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism\u002Flearning disorders)\n* Relapse previously treated by chemo and\u002For radiation therapy\n* Genetic syndrome (e.g. Down)\n* Unable to perform MR imaging (claustrophobia, metallic implants like pacemaker\u002FICD\u002Fneurostimulator)",{"count":461,"type":19},120,[58],"The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning.\n\nAll included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.",[465,466,467,25,468,29],"Cognition","Brain Tumor","Magnetic Resonance Imaging","Glioma","2024-05-07",{"date":471,"type":40},"2024-05-08",{"date":473,"type":40},"2023-02-08",{"date":475,"type":19},"2027-02-01",{"name":350,"class":47},{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":483,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":48},"100517304","predictive-value-of-serum-and-tissue-molecular-markers-and-imaging-features-in-the-invasiveness-and-prognosis-of-pituitary-neuroendocrine-tumors-100517304","NCT06015802","Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors","Inclusion Criteria:\n\nPatients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.\n\nExclusion Criteria:\n\n1. Previous pathological specimen suggested pituitary carcinoma.\n2. always have received radiation and chemotherapy or immune and targeted therapy of the patients.\n3. with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients.\n4. there are ectopic neuroendocrine tumor patients.\n5. within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery.\n6. crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis).\n7. peripheral glands or other solid tumors in patients with severe disease or blood system.\n8. serious organ damage such as heart, kidney, liver, etc.\n9. with severe mental or nervous system disease.\n10. serious high blood glucose or poorly controlled hypertension or emergency patients.",{"count":484,"type":19},300,"As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.",[29,487],"Neuroendocrine Tumors","2023-08-24",{"date":490,"type":40},"2023-08-29",{"date":492,"type":40},"2021-04-01",{"date":494,"type":19},"2029-03",{"name":496,"class":47},"Sun Yat-sen University",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":20,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":48},"100286902","phase-4-prophylactic-oral-antibiotics-on-sinonasal-outcomes-following-endoscopic-transsphenoidal-surgery-for-pituitary-lesions-100286902","NCT03014687","Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","POET","Inclusion Criteria:\n\n* Adult patient undergoing endoscopic surgery for resection of pituitary tumors for nonfunctioning adenoma, acromegaly, or prolactinoma\n* Adults \\>18 and \\\u003C85 years of age\n* English speaking and able to understand the ASK Nasal-12 and SNOT-22 scales\n* Free of any physical, mental, or medical condition which, in the opinion of the investigator, makes study participation inadvisable\n\nExclusion Criteria:\n\n* Anaphylaxis\u002Fintolerance to the study drugs\n* Cirrhosis, hepatitis\n* Any solid organ transplant or bone marrow transplant. And any patient felt to be immunocompromised by the investigators\n* Renal failure on dialysis\n* Any subject who is unwilling or unable to sign informed consent for the study\n* Pregnancy\n* Incarcerated patients\n* Cushing's disease\n* Rathke's Cleft cyst or pituitary cyst\n* History of chronic sinusitis\n* Anticipated use of nasal splints\n* Anticipated use of nasal septal flap\n* Active sinusitis\n* Nasal polyps\n* Previous sinus surgery\n* Concurrent antibiotics for another indication (i.e., urinary tract infection)\n* Immunodeficiency","84 Years",{"count":507,"type":19},116,[252],"To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.",[511,29],"Antibiotics",[112],"2018-08-13",{"date":515,"type":40},"2018-08-15",{"date":517,"type":40},"2017-07-01",{"date":519,"type":19},"2019-07",{"name":521,"class":47},"St. Joseph's Hospital and Medical Center, Phoenix"]